

---

## **Table of Contents**

<b>Index of Figures and Tables.....</b>	<b>4</b>
<b>Abbreviations and nomenclature.....</b>	<b>6</b>
<b>Abstract.....</b>	<b>8</b>
<b>1. Introduction.....</b>	<b>10</b>
1.1 Rett syndrome.....	10
1.2 Mental Retardation.....	11
1.2.1 Mutations in MECP2 cause Rett syndrome.....	12
1.3 Gene expression regulation.....	14
1.3.1 Transcription regulation.....	14
1.3.2 Epigenetic gene expression regulation.....	17
1.3.3 DNA methylation.....	18
1.4 MBD proteins.....	20
1.4.1 MBD1.....	21
1.4.2 MBD2.....	22
1.4.3 MBD3.....	24
1.4.4 MBD4.....	24
1.5 MECP2.....	25
1.5.1 Human MECP2: Gene structure and mutations .....	25
1.5.2 MECP2: Protein structure.....	27
1.5.3 MECP2: Function.....	29
1.5.4 MECP2: Expression.....	30
1.6 Techniques.....	31
1.6.1 DNA microarrays.....	31
1.6.2 Chromatin immunoprecipitation.....	32
1.7 Open questions and approaches.....	33
1.8 Goals of the thesis.....	34
<b>2. Materials and Methods.....</b>	<b>35</b>
2.1 Materials.....	35
2.1.1 Chemicals.....	35
2.1.2 Labware.....	35
2.1.3 Kits.....	35
2.1.4 Vectors.....	35
2.1.5 Bactrial strains.....	35
2.1.6 Oligonucleotides.....	36
2.1.7 Antibodies.....	36
2.1.8 Animals.....	36
2.1.9 Cell culture.....	36

---

2.1.10 Cell lines and primary cells.....	37
2.1.11 Bioinformatics databases and tools.....	37
2.2 Methods.....	38
2.2.1 Bioinformatics methods.....	38
2.2.1.1 Database screens.....	38
2.2.1.2 Blast searches.....	39
2.2.1.3 Sequence comparison.....	40
2.2.1.4 Perl scripts.....	40
2.2.2 cDNA microarrays.....	41
2.2.2.1 Microarray production.....	41
2.2.2.2 Microarray hybridization and washing.....	42
2.2.2.3 Image acquisition and data analysis.....	43
2.2.3 Cell culture.....	44
2.2.3.1 Coating of culture flasks.....	44
2.2.3.2 Primary fibroblasts.....	44
2.2.3.3 Lymphoblastoid cell line.....	45
2.2.3.4 Primary neurons.....	45
2.2.3.5 Glucocorticoid treatment of primary neurons.....	45
2.2.3.6 CCRF-CEM.....	46
2.2.3.7 NEURO-2A.....	46
2.2.4 Molecular biology techniques.....	46
2.2.4.1 DNA isolation.....	46
2.2.4.2 RNA isolation.....	47
2.2.4.3 Standard PCR.....	47
2.2.4.4 cDNA synthesis and subsequent gene-specific PCR (RT-PCR).....	48
2.2.4.5 Agarose gel electrophoresis.....	49
2.2.4.6 Sequencing.....	49
2.2.4.8 Chromatin immunoprecipitation.....	51
2.2.4.9 Bisulfite sequencing.....	53
<b>3. Results.....</b>	<b>55</b>
3.1 MBD protein family.....	55
3.1.1 Objective.....	55
3.1.2 Human MBD proteins.....	56
3.1.3 Domain analysis.....	59
3.1.4 MBD proteins in other species.....	61
3.1.5 Expression patterns of MBD genes.....	63
3.2 Search for MECP2 paralogues.....	64
3.2.1 Objective.....	64
3.2.2 Proteins with an overall sequence similarity to MECP2.....	65

---

3.3 MECP2 target genes.....	68
3.3.1 Objective.....	68
3.3.2 Genes differentially expressed in Mecp2-null mice – a microarray study.....	69
3.3.3 Localization of MECP2, FKBP5, and SGK in mouse brain.....	71
3.3.4 Establishment of chromatin immunoprecipitation (ChIP).....	73
3.3.5 MECP2 binding sites in the genomic regions of Fkbp5.....	74
3.3.6 MECP2 and the glucocorticoid receptor compete for binding to the GRE_2 locus.....	78
<b>4. Discussion.....</b>	<b>80</b>
4.1 MBD protein family.....	80
4.1.1 Expression of new MBD protein family members .....	80
4.1.2 The MBD domain of the new family members.....	81
4.2 Search for MECP2 paralogues.....	84
4.2.1 NEFH.....	84
4.2.2 MLLT2.....	85
4.3 MECP2 target genes.....	86
4.3.1 MECP2 regulates Fkbp5 expression.....	86
4.3.2 Northern blot and quantitative real-time PCR results support the microarray findings.....	87
4.3.3 Up-regulation of glucocorticoid–inducible Fkbp5 and Sgk in Mecp2-null animals is not due to elevation of glucocorticoid levels .....	89
4.3.4 Rett syndrome: a stress pathway disease - supporting evidence from the literature.....	91
4.3.5 Repression by MECP2: global and total versus local and partial.....	92
4.3.6 DNA microarray studies and chromatin immunoprecipitation.....	92
4.3.7 Future studies.....	93
4.4 Conclusions.....	94
<b>5. Zusammenfassung.....</b>	<b>95</b>
<b>6. Annex.....</b>	<b>97</b>
6.1 Sequence alignment of MECP2 and NEFH.....	97
<b>7. References.....</b>	<b>98</b>
<b>Acknowledgments.....</b>	<b>110</b>
<b>Curriculum Vitae and Publications.....</b>	<b>111</b>

## Index of Figures and Tables

### Tables

<b>Abbreviations</b> .....	6
<b>Table 1.</b> Mental retardation is the most important cost factor for the health care system.....	11
<b>Table 2.</b> The four RTT mouse models.....	13
<b>Table 3.</b> Primary antibodies used for ChIP and immunohistochemistry.....	36
<b>Table 4.</b> Secondary antibodies used for immunohistochemistry.....	36
<b>Table 5.</b> Media and other cell culture components.....	37
<b>Table 6.</b> Databases used in the different projects of this thesis.....	37
<b>Table 7.</b> Bioinformatics tools used in this thesis.....	38
<b>Table 8.</b> Primer pairs used for the amplification of plasmid inserts for the array production.....	41
<b>Table 9.</b> PCR conditions used for the amplification of cDNAs for the microarray.....	42
<b>Table 10.</b> Scheme depicting the amounts and concentrations of chemicals used for glucocorticoid treatment experiments.....	46
<b>Table 11.</b> Standard PCR temperature profile and PCR mix.....	48
<b>Table 12.</b> Touchdown PCR temperature profile and PCR mix.....	48
<b>Table 13.</b> Primers used for the amplification of gene specific PCR products from cDNA templates.....	49
<b>Table 14.</b> Temperature profile and PCR mix for sequencing reactions with M13 primers.....	50
<b>Table 15.</b> PCR mix for SR1 and SR2 reaction.....	52
<b>Table 16.</b> Temperature profile for SR1 and SR2 PCR reaction.....	52
<b>Table 17.</b> Primer used to amplify DNA fragments precipitated by ChIP.....	53
<b>Table 18.</b> Composition of the ChIP buffers not included in the Upstate ChIP Kit.....	53
<b>Table 19.</b> Primers used for bisulfite sequencing of the regions 1_4, 2_1, 2_2, and 2_4.....	54
<b>Table 20.</b> Protein domain and protein family databases.....	55
<b>Table 21.</b> Summary of the human MBD polypeptides.....	57
<b>Table 22.</b> Mouse homologues to human MBD proteins.....	62
<b>Table 23.</b> Expression patterns of the mouse/human MBD genes.....	63
<b>Table 24.</b> Results of the database queries.....	66
<b>Table 25.</b> Gene expression changes in the brain of an <i>Mecp2<sup>-ly</sup></i> animal compared to a <i>wt</i> litter mate control detected by microarray hybridizations.....	70
<b>Table 26.</b> The existence of amino acids important for m <sup>5</sup> CpG binding in MBD1 in other MBD protein family members.....	82
<b>Table 27.</b> Residues of the MBD of MECP2 and their function.....	83
<b>Table 28.</b> Classification of <i>Mecp2</i> -null mice according to the manifestation of phenotype.....	88

## Figures

<b>Fig. 1.</b> Transcription initiation.....	16
<b>Fig. 2.</b> Representation of an eukaryotic promoter.....	17
<b>Fig. 3.</b> Summary of epigenetic mechanisms.....	18
<b>Fig. 4.</b> Cytosines can get methylated at the 5' position.....	19
<b>Fig. 5.</b> Structure of the MBD domain of human MECP2.....	21
<b>Fig. 6.</b> Distribution and frequency of mutations in <i>MECP2e2</i> .....	25
<b>Fig. 7.</b> <i>MECP2</i> genomic, transcript, and protein structure.....	28
<b>Fig. 8.</b> Scheme of chromatin immunoprecipitation.....	32
<b>Fig. 9.</b> Alignment of the human methyl-CpG-binding proteins according to Swissprot.....	57
<b>Fig. 10.</b> Sequence logo of the eleven human MBD sequences.....	58
<b>Fig. 11.</b> Unrooted dendrogram depicting methyl-CpG-binding domains of the human protein family.....	59
<b>Fig. 12.</b> Northern blots for <i>KIAA1461/MBD5</i> and <i>KIAA1887/MBD6</i> .....	64
<b>Fig. 13.</b> DotPlot output of a comparison of MECP2 to itself.....	65
<b>Fig. 14.</b> Alignment of MECP2 (486 aa) and NEFH (1020 aa) derived from the SSDB.....	66
<b>Fig. 15.</b> Alignment of MECP2 (486 aa) and MLLT2 (2311 aa) derived from the SSDB.....	67
<b>Fig. 16.</b> Expression of MECP2, FKBP5, and SGK in the brain of adult female mice.....	72
<b>Fig. 17.</b> DNA fragment distribution obtained by sonication of chromatin.....	74
<b>Fig. 18.</b> Comparison of human <i>FKBP5</i> and mouse <i>Fkbp5</i> genomic regions.....	75
<b>Fig. 19.</b> PCR using mouse brain cDNA with primers specific for mouse <i>Fkbp5</i> .....	75
<b>Fig. 20.</b> Chromatin immunoprecipitation shows binding of MECP2 to the genomic region of <i>Fkbp5</i> .....	76
<b>Fig. 21.</b> Schematic representation of the mouse <i>Fkbp5</i> gene.....	77
<b>Fig. 22.</b> Methylation status of CpGs in <i>Fkbp5</i> genomic DNA determined by bisulfite sequencing.....	77
<b>Fig. 23.</b> <i>Fkbp5</i> intron/exon structure and the localization of GR response elements.....	78
<b>Fig. 24.</b> MECP2 and GR both bind to the GRE_2 genomic region.....	79
<b>Fig. 25.</b> Solution structure of the MBDS of MBD1 (left) and MECP2 (right).....	81
<b>Fig. 26.</b> Graphical representation of MECP2 with the low complexity regions depicted in blue.....	84
<b>Fig. 27.</b> Structure of the NEFH protein.....	85
<b>Fig. 28.</b> Model of <i>Fkbp5</i> gene regulation.....	87
<b>Fig. 29.</b> Northern blot and real-time PCR results confirm microarray data.....	89
<b>Fig. 30.</b> Hormone-dependent and hormone-independent induction of <i>Fkbp5</i> and <i>Sgk</i> in mouse brain.....	90
<b>Fig. 31.</b> MECP2 binding to the <i>Fkbp5</i> gene is not abolished in <i>wt</i> mouse brain upon corticosterone infusion as shown by CHIP with placebo and corticosterone-treated mice.....	90